Clovis Oncology (NASDAQ:CLVS) shares are surging in today’s pre-market trade after its Rubraca demonstrated progression-free survival versus placebo for ovarian cancer.
The company presented the data from the supporting ATHENA trial at the European Society of Medical Oncology (ESMO) Congress in Paris.
More details to follow…
Read full Disclosure
